scholarly journals Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base

Cancer ◽  
2020 ◽  
Vol 126 (17) ◽  
pp. 4013-4022
Author(s):  
Abiola Ibraheem ◽  
Olufunmilayo I. Olopade ◽  
Dezheng Huo
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Data Base ◽  
Prognostic Value ◽  
Propensity Score Analysis ◽  
National Cancer Data Base ◽  
Diverse Populations ◽  
Cancer Data ◽  
Genomic Assays ◽  
Score Analysis

scholarly journals The national cancer data base report on breast cancer

Cancer ◽  
1994 ◽  
Vol 73 (7) ◽  
pp. 1994-2000 ◽  
Author(s):  
Robert T. Osteen ◽  
Lucy Hynds Karnell
Keyword(s):  
Breast Cancer ◽  
Data Base ◽  
National Cancer Data Base ◽  
Cancer Data

Breast-Conserving Therapy is Associated with Better Survival than Mastectomy in Early-Stage Breast Cancer: A Propensity Score Analysis

2021 ◽  
Author(s):  
Jiali Ji ◽  
Shushu Yuan ◽  
Jiawei He ◽  
Hong Liu ◽  
Lei Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Propensity Score ◽  
Cancer Patients ◽  
Propensity Score Analysis ◽  
Early Stage ◽  
Breast Conserving Therapy ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Kaplan Meier ◽  
Score Analysis

Abstract Background: Recent retrospective studies have reported that breast-conserving therapy (BCT) led to improved overall survival (OS) than mastectomy in some populations. We aimed to compare the efficacy of BCT and mastectomy using the SEER database. Methods: Between 2010 and 2015, 99,790 eligible patients were identified. We included early-stage breast cancer patients with 5cm or smaller tumors and three or fewer positive lymph nodes in our study. We compared the OS results among patients with BCT and mastectomy. Kaplan-Meier plots, Cox proportional hazard regressions were used to evaluate the outcomes. Propensity-score matching was used to assemble a cohort of patients with similar baseline characteristics. Results: In our study, 77,452 (77.6%) patients underwent BCT and 22,338 (22.4%) underwent mastectomy. The 5-year OS rate was 94.7% in the BCT group and 87.6% in the mastectomy group (P <0.001). After matching, multivariate analysis in the matched cohort showed that women underwent mastectomy was associated with worse OS results compared with those with BCT (Hazard ratio (HR) = 1.628; 95% confidence intervals (CIs) = 1.445- 1.834, P<0.001). Patients with different subtypes and age group (>50 years old; ≤50 years old) received BCT all showed significantly better OS than those received mastectomy. The effect of surgery choice on survival was the same in matched and all cohorts. Conclusions: Our study showed that BCT was associated with improved survival compared with mastectomy in early-stage breast cancer patients. It seems advisable to encourage patients to receive BCT rather than mastectomy in early-stage patients when feasible and appropriate.

Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer

2017 ◽  
Vol 27 (9) ◽  
pp. 1904-1911 ◽  
Author(s):  
Nataniel H. Lester-Coll ◽  
Melissa R. Young ◽  
Henry S. Park ◽  
Elena S. Ratner ◽  
Babak Litkouhi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Propensity Score ◽  
Confidence Interval ◽  
Data Base ◽  
Adjuvant Treatment ◽  
Odds Ratio ◽  
National Cancer Data Base ◽  
Stage Ii ◽  
Cancer Data

ObjectiveRadiotherapy (RT) is an established adjuvant treatment for stage II endometrioid endometrial carcinoma (EEC). The role of chemotherapy (CT) in stage II EEC is less proven. We used the National Cancer Data Base to identify factors associated with adjuvant CT in stage II EEC and to explore whether receipt of CT was associated with improved overall survival (OS).Methods/MaterialsWomen diagnosed in 2010 to 2013 with International Federation of Obstetrics and Gynecology stage II EEC (grades 1–3) after hysterectomy and bilateral salpingo-oophorectomy were identified in the National Cancer Data Base. Multivariable logistic regression was used to identify covariates associated with receipt of CT. Overall survival among patients receiving RT, CT, or chemoradiotherapy (CRT) after surgery was compared using Kaplan-Meier estimates, the log-rank test, Cox proportional hazards regression, and propensity score matching.ResultsWe identified 6102 stage II EEC patients. There were 358 patients (6%) who received adjuvant CT alone and 525 (9%) who received CRT; the remainder received RT alone (n = 1906; 31%) or no adjuvant treatment (n = 3313; 54%). The presence of lymphovascular invasion (odds ratio, 3.58;P< 0.001) and grade 3 disease (odds ratio, 3.40;P< 0.001) was strongly associated with receipt of CT or CRT. The OS at 3 years for the entire cohort was 89%. On multivariable analysis, CT versus RT was associated with worse OS (hazard ratio [HR], 2.12 [95% confidence interval, 1.46–3.06];P< 0.001), whereas CRT versus RT was not associated with improved OS (HR, 1.07 [95% confidence interval, 0.71–1.62];P= 0.781). After propensity score matching, there remained no difference in OS between RT and CRT (HR, 1.14;P= 0.614).ConclusionsPatients with stage II EEC have an excellent prognosis, and most undergo observation or receive adjuvant RT in the United States. Receipt of CT (alone or with RT) was not associated with an OS advantage compared with RT alone in this observational cohort. Randomized trials will help clarify the role of CT in stage II patients.

Sign in / Sign up

Export Citation Format

Share Document